GSA Capital Partners LLP decreased its holdings in shares of Clearside Biomedical Inc (NASDAQ:CLSD) by 45.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,018 shares of the company’s stock after selling 104,858 shares during the period. GSA Capital Partners LLP owned about 0.34% of Clearside Biomedical worth $123,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the business. Deutsche Bank AG increased its stake in Clearside Biomedical by 487.2% during the fourth quarter. Deutsche Bank AG now owns 536,761 shares of the company’s stock valued at $573,000 after purchasing an additional 445,346 shares during the last quarter. Geode Capital Management LLC increased its stake in Clearside Biomedical by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 303,512 shares of the company’s stock valued at $324,000 after purchasing an additional 14,181 shares during the last quarter. Parallel Advisors LLC bought a new stake in Clearside Biomedical during the first quarter valued at $87,000. Finally, SG Americas Securities LLC increased its stake in Clearside Biomedical by 63.4% during the first quarter. SG Americas Securities LLC now owns 57,234 shares of the company’s stock valued at $79,000 after purchasing an additional 22,213 shares during the last quarter. Hedge funds and other institutional investors own 11.95% of the company’s stock.
Several analysts have weighed in on CLSD shares. Laidlaw lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Needham & Company LLC lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Friday, August 9th. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. JMP Securities set a $3.00 target price on shares of Clearside Biomedical and gave the company a “buy” rating in a research note on Thursday, August 22nd. Finally, Zacks Investment Research upgraded shares of Clearside Biomedical from a “hold” rating to a “strong-buy” rating and set a $1.50 target price for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $3.64.
Clearside Biomedical stock opened at $0.67 on Monday. The company has a 50-day simple moving average of $0.99 and a 200-day simple moving average of $1.18. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.47 and a current ratio of 3.47. Clearside Biomedical Inc has a one year low of $0.56 and a one year high of $6.80.
Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.05 million. On average, research analysts predict that Clearside Biomedical Inc will post -0.98 earnings per share for the current fiscal year.
Clearside Biomedical Profile
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Featured Article: Bollinger Bands
Want to see what other hedge funds are holding CLSD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clearside Biomedical Inc (NASDAQ:CLSD).
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.